结直肠癌肝转移动脉化疗栓塞与全身静脉化疗的疗效对比分析

Therapeutic Efficacy of Liver Metastasis from Colorectal Cancer:Comparative Analysis between Transcatheter Arteial Chemoembolization and Systemic Chemotherapy

目的通过比较经肝动脉灌注化疗栓塞与全身静脉化疗治疗结直肠癌肝转移的疗效及生存率,旨在为临床制定合理治疗方案提供依据。资料与方法回顾性分析45例临床分期相同但治疗方法不同的结直肠癌患者资料,将其分为肝动脉化疗栓塞组及全身静脉化疗组。其中肝动脉灌注化疗栓塞治疗组27例,全身静脉化疗组18例。两组均采用Folfox方案化疗,治疗前后行血常规、肝肾功能及肝脏增强CT检查。随访其生存结果,分析两组的完全缓解(CR)、部分缓解(PR)及1、2、3年生存率。结果肝动脉化疗栓塞组的CR、PR率(20%、35%)显著高于静脉化疗组(6.25%、25%)(P<0.05);肝动脉灌注化疗组的中位生存期为(25±0.5)个月,明显高于全身静脉化疗组生存期(13±0.5)个月;肝动脉灌注化疗组的1、2、3年生存率(62.96%、48.14%、22.2%)也显著高于静脉化疗组(38.89%、16.67%、0%)(P<0.05)。结论肝动脉灌注化疗栓塞治疗结肠癌肝转移优于全身静脉化疗。

Objective To compare the therapeutic efficacy of transcatheter arterial chemoembolization（TACE） with systemic chemotherapy（SC） in treatment of liver metastases from colorectal cancer.Materials and Methods Forty-five patients with liver metastases from colorectal cancer were randomly divided into TACE group（27cases）and SC group（18cases）.Folfox chemtherapy regime was used in both two groups.CR,PR and 1,2,3 year survival rates of two groups were analyzed.Results CR,PR in TACE group was significantly higher than that in SC group（20% vs.6.25%;35% vs.25%,P0.05,respectively）.1,2,and 3 year survival rates in TACE group were significantly higher than those in SC group（62.96% vs.38.89%;48.14% vs.16.67%;22.2% vs.0%,P0.05,respectively）.For TACE group,the median survival period was（25±0.5）month,which significantly higher than those in SC group（13±0.5）month.Conclu-sion TACE has better therapeutic efficacy than SC in liver metastases from colonrectal cancer.